VivoSeq
Other

Phase II

0

Pipeline Programs

32

Active Trials

60

Companies Involved

Phase II is an early-stage landscape with 0 programs across 60 companies. The most active players are AstraZeneca, Bristol-Myers Squibb, Bayer.

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

25/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

229

clinical trials

Completed141 · 62%
Terminated26 · 11%
Unknown status25 · 11%
Recruiting13 · 6%
Active, not recruiting12 · 5%
Not yet recruiting7 · 3%
Other5 · 2%

Trial Activity

229 trials

Phase II Study of LM-24C5
Recruiting·LLaNova Medicines Limited·Phase 2·NCT07387081·130 enrolled
Phase II Trial of Lung Chemoemobolization
Recruiting··Phase 2·NCT05672108·30 enrolled
Biological Effects of Quercetin in COPD Phase II
Recruiting·TTemple University·Phase 2·NCT06003270·30 enrolled
Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors
Recruiting··Phase 2·NCT06553365·30 enrolled
Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)